CoChat

Outcomes of hyperbolic tapering of antidepressants

Open access
van Os, Jim, Groot, Peter C. · 2023 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 6 of the 26 sources its claims cite were checked for support.

Abstract

Background: In patients attempting to discontinue their antidepressant medication, there have been no prospective studies on patterns of withdrawal as a function of the rate of antidepressant reduction during the tapering trajectory, and moderators thereof. Objective: To investigate withdrawal as a function of gradual dose reduction. Design: Prospective cohort study. Methods: The sampling frame consisted of 3956 individuals in the Netherlands who received an antidepressant tapering strip between 19 May 2019 and 22 March 2022 in routine clinical practice. Of these, 608 patients, majorly with previous unsuccessful attempts to stop, provided daily ratings of withdrawal in the context of reducing their antidepressant medications (mostly venlafaxine or paroxetine), using hyperbolic tapering strips offering daily tiny reductions in dose. Results: Withdrawal in daily-step hyperbolic tapering trajectories was limited, and inverse to the rate of taper. Female sex, younger age, presence of one or more risk factors and faster rate of reduction over shorter tapering trajectories were associated with more withdrawal and differential course over time. Thus, sex and age differences were less marked early in the course of the trajectory, whereas differences associated with risk factors and shorter trajectories tended to peak early in the trajectory. There was evidence that tapering in weekly larger steps (mean per-week dose reduction: 33.4% of previous dose), in comparison with daily tiny steps (mean per-day dose reduction: 4.5% of previous dose or 25.3% per week), was associated with more withdrawal in trajectories of 1, 2 or 3 months, particularly for paroxetine and the group of other (non-paroxetine, non-venlafaxine) antidepressants. Conclusion: Antidepressant hyperbolic tapering is associated with limited, rate-dependent withdrawal that is inverse to the rate of taper. The demonstration of multiple demographic, risk and complex temporal moderators in time series of withdrawal data indicates that antidepressant tapering in clinical practice requires a personalised process of shared decision making over the entire course of the tapering period.

Overview

CoChat Summary

TL;DR

In a prospective cohort of 608 people using hyperbolic antidepressant tapering strips, withdrawal during daily tiny-step tapering was limited and inversely related to taper rate. Female sex, younger age, more risk factors, and shorter/faster tapering trajectories were associated with more withdrawal and different withdrawal course over time.

Key findings

Withdrawal scores in daily-step hyperbolic tapering varied between “2” (very little) and “3” (a little), and withdrawal was rate-dependent, approximating a mirror image of dose reduction.

  • In adjusted multilevel regression, female sex was associated with more withdrawal (b = 0.24, p = 0.003), and older age with less withdrawal versus age ≤35 (36–60: b = −0.16, p = 0.040; >60: b = −0.32, p = 0.001).
  • More risk factors were associated with more withdrawal (linear trend b = 0.11, p < 0.001), and longer tapering trajectories with less withdrawal (linear trend b = −0.13, p < 0.001).
  • Daily tiny-step tapering averaged 4.5% dose reduction per day (25.3% per week), while weekly large-step tapering averaged 33.4% per step; weekly large-step tapering showed directionally more withdrawal (b = 0.14, p = 0.247) and a significant interaction with time (p < 0.001), especially in 1–3 month trajectories for paroxetine and other antidepressants.

Methods

Prospective cohort study using a national sampling frame of 3,956 individuals in the Netherlands who received an antidepressant tapering strip between 19 May 2019 and 22 March 2022; 608 provided daily withdrawal ratings, yielding 32,368 observations.

  • Participants mostly used venlafaxine or paroxetine and rated daily suffering due to withdrawal on a 1–7 scale; tapering was mostly daily tiny steps, with a small weekly large-step comparison group.
  • Panel data were modeled with multilevel random regression in Stata version 16, with standardized withdrawal as the response and age, sex, antidepressant type, risk factors, time, trajectory length, and dose as explanatory variables; interactions with time were examined and visualized with marginsplots.

Limitations

The paper states that the observational design limits causal inference, and that the association between stabilisation strips and withdrawal likely reflects reverse causality; the main rate-of-reduction association is argued to be likely causal.

  • The paper states the sample may not be representative due to extensive attrition and socioeconomic selection, since Dutch insurers typically reimburse only 1–3 months of tapering strips while real-life tapering may take years; trajectory length also reflects the sampling period, not necessarily total tapering time, and many trajectories are partial.
  • The paper notes the weekly large-step versus daily tiny-step comparison was imprecise due to the small large-step group, antidepressant indication was unknown, and withdrawal assessment was subjective self-report; evident from the text, the study cannot inform what happens after patients taper completely.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20451253231171518

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Marginsplot of interaction between time and sex in the model of standardised withdrawal ratings.
Figure 1. Marginsplot of interaction between time and sex in the model of standardised withdrawal ratings.CC BY · PubMed Central
Figure 2. Marginsplot of interaction between time and age group in the model of standardised withdrawal ratings.
Figure 2. Marginsplot of interaction between time and age group in the model of standardised withdrawal ratings.CC BY · PubMed Central
Figure 3. Marginsplot of interaction between time and risk load in the model of standardised withdrawal ratings.
Figure 3. Marginsplot of interaction between time and risk load in the model of standardised withdrawal ratings.CC BY · PubMed Central
Figure 4. Marginsplot of interaction between time and length of tapering trajectory in the model of standardised withdrawal ratings.
Figure 4. Marginsplot of interaction between time and length of tapering trajectory in the model of standardised withdrawal ratings.CC BY · PubMed Central
Figure 5. Course of daily withdrawal ratings (below) during hyperbolic antidepressant tapering (above), shown as weekly dose reduction expressed as percentage of initial dose, stratified by length of tapering trajectory.
Figure 5. Course of daily withdrawal ratings (below) during hyperbolic antidepressant tapering (above), shown as weekly dose reduction expressed as percentage of initial dose, stratified by length of tapering trajectory.CC BY · PubMed Central
Figure 6. Marginsplot of interaction between time and type of tapering (daily tiny steps versus weekly large steps) in the model of standardised withdrawal ratings.
Figure 6. Marginsplot of interaction between time and type of tapering (daily tiny steps versus weekly large steps) in the model of standardised withdrawal ratings.CC BY · PubMed Central
Figure 7. Marginsplot of interaction between time and type of tapering (daily tiny steps versus weekly large steps) in the model of standardised withdrawal ratings, by medication type.
Figure 7. Marginsplot of interaction between time and type of tapering (daily tiny steps versus weekly large steps) in the model of standardised withdrawal ratings, by medication type.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 15 Not checked · 57 Own results and interpretations

37 more claims

Create a free account to see all 76 claims and to verify the 20 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 7 · the rest aren’t loaded

2 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 27 references

Research works printed but not linked: 6

  1. Fava M, 2006, J Clin Psychiatry, 67, 14
  2. Chankova S, 2022, The Economist, 66
  3. Davies J, 2019, BMJ, 365
  4. Mitchell KM, 1997, BJPsych, 170, 288
  5. Groot PC, 2013, Tijdschr Psychiatr, 55, 789
  6. Ruhe HG, 2020, Ned Tijdschr Geneeskd, 164

Cited by

See all 22

Metadata

Authors
van Os, J., & Groot, P. C.
Affiliations
  • Department Psychiatry, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands
  • University Medical Center Utrecht (NL)
Venue
Therapeutic Advances in Psychopharmacology
Published
2023-01
Volume
13
Pages
20451253231171518-20451253231171518
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4377093714
Cited by
22
References
27
Citations by year
2026: 10 · 2025: 7 · 2024: 3 · 2023: 2
FWCI
3.41
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by-nc)
  • Research Publications (Maastricht University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
antidepressant tapering, antidepressant discontinuation, venlafaxine, paroxetine, sex differences, age differences, shared decision-making, drug discontinuation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of hyperbolic tapering of antidepressants. https://app.cochat.ai/papers/10.1177/20451253231171518
The paper
van Os, J., & Groot, P. C. (2023). Outcomes of hyperbolic tapering of antidepressants. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231171518

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.